Giuliana Guerrizio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Giuliana Guerrizio has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Agnese Viscido
Microbiology and Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy
1 shared publication - Alessandra Pierangeli
Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
1 shared publication - Carla Prezioso
Department for the Promotion of Human Sciences and Quality of Life, San Raffaele University, Via di Val Cannuta 247, 00166 Rome, Italy
1 shared publication - Carolina Scagnolari
Department of Molecular Medicine, Laboratory of Virology Sapienza University of Rome Rome Italy
1 shared publication - Donatella Maria Rodio
Laboratory of Microbiology and Virology, Department of Molecular Medicine, “Sapienza” University of Rome, 00161 Rome, Italy
1 shared publication - Federica Frasca
Department of Public Health and Infectious Diseases, University of Rome Sapienza, 00185 Rome, Italy
1 shared publication
Latest Publications
- Open Access
- 9 June 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (6) , 1259
KI and WU Polyomavirus in Respiratory Samples of SARS-CoV-2 Infected Patients
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has been declared a global pandemic. Our goal was to determine whether co-infections with respiratory polyomaviruses, such as Karolinska Institutet polyomavirus (KIPyV) and Washington University polyomavirus (WUPyV) occur in SARS-CoV-2 infected patients. Oropharyngeal swabs from 150 individuals, 112 symptomatic COVID-19 patients and 38 healthcare workers not infected by SARS-CoV-2, were collected from March 2020 through May 2020 and tested for KIPyV and WUPyV DNA presence. Of the 112 SARS-CoV-2 positive patients, 27 (24.1%) were co-infected with KIPyV, 5 (4.5%) were positive for WUPyV, and 3 (2.7%) were infected simultaneously by KIPyV and WUPyV. Neither KIPyV nor WUPyV DNA was detected in samples of healthcare workers. Significant correlations were found in patients co-infected with SARS-CoV-2 and KIPyV (p < 0.05) and between SARS-CoV-2 cycle threshold values and KIPyV, WUPyV and KIPyV and WUPyV concurrently detected (p < 0.05). These results suggest that KIPyV and WUPyV may behave as opportunistic respiratory pathogens. Additional investigations are needed to understand the epidemiology and the prevalence of respiratory polyomavirus in COVID-19 patients and whether KIPyV and WUPyV could potentially drive viral interference or influence disease outcomes by upregulating SARS-CoV-2 replicative potential.
- 9 June 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (6) , 1259
Open AccessKI and WU Polyomavirus in Respiratory Samples of SARS-CoV-2 Infected Patients
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has been declared a global pandemic. Our goal was to determine whether co-infections with respiratory polyomaviruses, such as Karolinska Institutet polyomavirus (KIPyV) and Washington University polyomavirus (WUPyV) occur in SARS-CoV-2 infected patients. Oropharyngeal swabs from 150 individuals, 112 symptomatic COVID-19 patients and 38 healthcare workers not infected by SARS-CoV-2, were collected from March 2020 through May 2020 and tested for KIPyV and WUPyV DNA presence. Of the 112 SARS-CoV-2 positive patients, 27 (24.1%) were co-infected with KIPyV, 5 (4.5%) were positive for WUPyV, and 3 (2.7%) were infected simultaneously by KIPyV and WUPyV. Neither KIPyV nor WUPyV DNA was detected in samples of healthcare workers. Significant correlations were found in patients co-infected with SARS-CoV-2 and KIPyV (p < 0.05) and between SARS-CoV-2 cycle threshold values and KIPyV, WUPyV and KIPyV and WUPyV concurrently detected (p < 0.05). These results suggest that KIPyV and WUPyV may behave as opportunistic respiratory pathogens. Additional investigations are needed to understand the epidemiology and the prevalence of respiratory polyomavirus in COVID-19 patients and whether KIPyV and WUPyV could potentially drive viral interference or influence disease outcomes by upregulating SARS-CoV-2 replicative potential.